S&P 500   3,363.00 (+0.83%)
DOW   27,781.70 (+1.20%)
QQQ   277.84 (+0.68%)
AAPL   115.81 (+1.51%)
MSFT   210.33 (+1.48%)
FB   261.90 (+0.04%)
GOOGL   1,465.60 (-0.03%)
AMZN   3,148.73 (+0.12%)
TSLA   429.01 (+2.37%)
NVDA   541.22 (+2.30%)
BABA   293.98 (+6.16%)
CGC   14.32 (-1.24%)
MU   46.96 (-7.39%)
GE   6.23 (+1.80%)
AMD   81.99 (+0.27%)
T   28.51 (+0.74%)
F   6.66 (+0.91%)
ACB   4.65 (-0.64%)
GILD   63.19 (+1.76%)
NFLX   500.03 (+1.33%)
DIS   124.08 (-1.05%)
BA   165.26 (+1.01%)
BAC   24.09 (+1.35%)
S&P 500   3,363.00 (+0.83%)
DOW   27,781.70 (+1.20%)
QQQ   277.84 (+0.68%)
AAPL   115.81 (+1.51%)
MSFT   210.33 (+1.48%)
FB   261.90 (+0.04%)
GOOGL   1,465.60 (-0.03%)
AMZN   3,148.73 (+0.12%)
TSLA   429.01 (+2.37%)
NVDA   541.22 (+2.30%)
BABA   293.98 (+6.16%)
CGC   14.32 (-1.24%)
MU   46.96 (-7.39%)
GE   6.23 (+1.80%)
AMD   81.99 (+0.27%)
T   28.51 (+0.74%)
F   6.66 (+0.91%)
ACB   4.65 (-0.64%)
GILD   63.19 (+1.76%)
NFLX   500.03 (+1.33%)
DIS   124.08 (-1.05%)
BA   165.26 (+1.01%)
BAC   24.09 (+1.35%)
S&P 500   3,363.00 (+0.83%)
DOW   27,781.70 (+1.20%)
QQQ   277.84 (+0.68%)
AAPL   115.81 (+1.51%)
MSFT   210.33 (+1.48%)
FB   261.90 (+0.04%)
GOOGL   1,465.60 (-0.03%)
AMZN   3,148.73 (+0.12%)
TSLA   429.01 (+2.37%)
NVDA   541.22 (+2.30%)
BABA   293.98 (+6.16%)
CGC   14.32 (-1.24%)
MU   46.96 (-7.39%)
GE   6.23 (+1.80%)
AMD   81.99 (+0.27%)
T   28.51 (+0.74%)
F   6.66 (+0.91%)
ACB   4.65 (-0.64%)
GILD   63.19 (+1.76%)
NFLX   500.03 (+1.33%)
DIS   124.08 (-1.05%)
BA   165.26 (+1.01%)
BAC   24.09 (+1.35%)
S&P 500   3,363.00 (+0.83%)
DOW   27,781.70 (+1.20%)
QQQ   277.84 (+0.68%)
AAPL   115.81 (+1.51%)
MSFT   210.33 (+1.48%)
FB   261.90 (+0.04%)
GOOGL   1,465.60 (-0.03%)
AMZN   3,148.73 (+0.12%)
TSLA   429.01 (+2.37%)
NVDA   541.22 (+2.30%)
BABA   293.98 (+6.16%)
CGC   14.32 (-1.24%)
MU   46.96 (-7.39%)
GE   6.23 (+1.80%)
AMD   81.99 (+0.27%)
T   28.51 (+0.74%)
F   6.66 (+0.91%)
ACB   4.65 (-0.64%)
GILD   63.19 (+1.76%)
NFLX   500.03 (+1.33%)
DIS   124.08 (-1.05%)
BA   165.26 (+1.01%)
BAC   24.09 (+1.35%)
Log in
NASDAQ:AKER

Akers Biosciences Stock Forecast, Price & News

$2.25
+0.09 (+4.17 %)
(As of 09/30/2020 05:22 PM ET)
Add
Compare
Today's Range
$2.16
Now: $2.25
$2.27
50-Day Range
$2.05
MA: $3.47
$6.54
52-Week Range
$1.55
Now: $2.25
$10.99
Volume237,972 shs
Average Volume1.39 million shs
Market Capitalization$19.63 million
P/E RatioN/A
Dividend YieldN/A
Beta0.1
Akers Biosciences, Inc., together with its subsidiaries, develops, manufactures, and supplies rapid screening and testing products designed to deliver healthcare information to healthcare providers and consumers in the United States, the People's Republic of China, and internationally. The company's marketed products include BreathScan, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor ketosis; and BreathScan Lync, a non-invasive, quantitative measurement of biological markers for health and wellness. Its marketed products also include PIFA Heparin/PF4 and PIFA PLUSS PF4 rapid tests for Heparin/PF4 antibodies to detect an allergy to the used blood thinner, Heparin; seraSTAT, a rapid blood cell separator; Tri-Cholesterol 'Check', a rapid test for total and high density lipoprotein cholesterol and estimates low density lipo protein; and BreathScan OxiCHek, a breath test for oxidative stress using the Lync reader and digital app. The company's pipeline products comprise Breath Diabetic Ketoacidosis, a disposable breath ketone device for diabetic monitoring; Breath PulmoHealth 'Check', a suite of breath tests for biomarkers indicating asthma, chronic obstructive pulmonary disease, and lung cancer; PIFA PLUSS Chlamydia, a rapid test for sexually transmitted diseases; and BreathScan KetoChek, a breath test for ketosis using the Lync reader and digital app. Akers Biosciences, Inc. was founded in 1989 and is headquartered in Thorofare, New Jersey.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.71 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AKER
CUSIPN/A
Phone856-848-8698

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.58 million
Book Value$5.38 per share

Profitability

Net Income$-3,890,000.00
Net Margins-489.84%

Miscellaneous

Employees13
Market Cap$19.63 million
Next Earnings Date9/30/2020 (Estimated)
OptionableNot Optionable
$2.25
+0.09 (+4.17 %)
(As of 09/30/2020 05:22 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AKER News and Ratings via Email

Sign-up to receive the latest news and ratings for AKER and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Akers Biosciences (NASDAQ:AKER) Frequently Asked Questions

How has Akers Biosciences' stock been impacted by Coronavirus?

Akers Biosciences' stock was trading at $2.26 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AKER shares have decreased by 0.4% and is now trading at $2.25.
View which stocks have been most impacted by COVID-19
.

When is Akers Biosciences' next earnings date?

Akers Biosciences is scheduled to release its next quarterly earnings announcement on Wednesday, September 30th 2020.
View our earnings forecast for Akers Biosciences
.

How were Akers Biosciences' earnings last quarter?

Akers Biosciences Inc (NASDAQ:AKER) issued its quarterly earnings data on Thursday, November, 15th. The medical instruments supplier reported ($0.26) earnings per share (EPS) for the quarter. The medical instruments supplier earned $0.56 million during the quarter. Akers Biosciences had a negative net margin of 489.84% and a negative return on equity of 107.05%.
View Akers Biosciences' earnings history
.

Are investors shorting Akers Biosciences?

Akers Biosciences saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 402,800 shares, an increase of 86.1% from the August 31st total of 216,400 shares. Based on an average daily volume of 1,260,000 shares, the short-interest ratio is presently 0.3 days. Approximately 4.8% of the company's stock are short sold.
View Akers Biosciences' Short Interest
.

Who are some of Akers Biosciences' key competitors?

What other stocks do shareholders of Akers Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akers Biosciences investors own include ImmunoGen (IMGN), Sorrento Therapeutics (SRNE), AVEO Pharmaceuticals (AVEO), Advanced Micro Devices (AMD), Aytu Bioscience (AYTU), Biopharmx (BPMX), Neovasc (NVCN), Vaxart (VXRT), Anavex Life Sciences (AVXL) and Micron Technology (MU).

Who are Akers Biosciences' key executives?

Akers Biosciences' management team includes the following people:
  • Mr. Howard R. Yeaton Jr., CPA, CEO & Interim CFO (Age 64)
  • Mr. Douglas Carrara, Sr. VP of Global Marketing & Commercial Operations
  • Ms. Pamela E. Hibler, VP of Sales & Distribution
  • Mr. Gary M. Rauch, VP of Fin. & Treasurer (Age 63)

What is Akers Biosciences' stock symbol?

Akers Biosciences trades on the NASDAQ under the ticker symbol "AKER."

How do I buy shares of Akers Biosciences?

Shares of AKER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Akers Biosciences' stock price today?

One share of AKER stock can currently be purchased for approximately $2.25.

How big of a company is Akers Biosciences?

Akers Biosciences has a market capitalization of $19.63 million and generates $1.58 million in revenue each year. Akers Biosciences employs 13 workers across the globe.

What is Akers Biosciences' official website?

The official website for Akers Biosciences is www.akersbio.com.

How can I contact Akers Biosciences?

Akers Biosciences' mailing address is 201 GROVE RD, THOROFARE NJ, 08086. The medical instruments supplier can be reached via phone at 856-848-8698 or via email at [email protected]

This page was last updated on 9/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.